Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Palbociclib and FES PET
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT02806050
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 21
- Registration Number
- NCT02806648
- Locations
- 🇪🇸
H.U.Virgen del Rocio, Sevilla, Spain
🇪🇸H. Castellon, Castelló, Spain
🇪🇸H.U.La Paz, Madrid, Spain
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- First Posted Date
- 2016-05-30
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 53
- Registration Number
- NCT02785939
- Locations
- 🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT02778685
- Locations
- 🇺🇸
City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Antelope Valley, Lancaster, California, United States
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 12
- Registration Number
- NCT02774681
- Locations
- 🇺🇸
Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Houston Methodist Hospital/Houston Methodist Cancer Center, Houston, Texas, United States
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 195
- Registration Number
- NCT02764541
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Dana-Farber at St. Elizabeth's Medical Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 37
- Registration Number
- NCT02760030
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Case Western University, Cleveland, Ohio, United States
🇺🇸St. Elizabeth Healthcare, Edgewood, Kentucky, United States
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 60
- Registration Number
- NCT02738866
- Locations
- 🇺🇸
Reading Hospital - McGlinn Cancer Institute, West Reading, Pennsylvania, United States
🇺🇸Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Interventions
- Drug: SunitinibDrug: Trastuzumab and PertuzumabDrug: Vemurafenib and CobimetinibDrug: PalbociclibDrug: Nivolumab and IpilimumabDrug: AbemaciclibDrug: Atezolizumab and PHESGODrug: Atezolizumab and TalazoparibDrug: Tucatinib plus Trastuzumab Subcutaneous (SC)Drug: FutibatinibDrug: TalazoparibDrug: TemsirolimusDrug: RegorafenibDrug: OlaparibDrug: PembrolizumabDrug: EntrectinibDrug: Larotrectinib
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 3791
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Celcuity Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02684032
- Locations
- 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Karmanos Cancer Institute, Farmington Hills, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.